Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The platelet-lymphocyte ratio (PLR) predicts survival in non-small cell lung cancer (NSCLC) patients treated with first or second-generation EGFR tyrosine kinase inhibitors (TKIs). Third-generation TKIs like osimertinib show efficacy regardless of PLR.
Area Of Science
- Oncology
- Biomarkers
- Cancer Therapeutics
Background
- The predictive value of laboratory markers, specifically the platelet-lymphocyte ratio (PLR), in non-small cell lung cancer (NSCLC) patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) requires further investigation.
- The impact of TKI generation on the predictability of PLR for survival outcomes remains undetermined.
Purpose Of The Study
- To evaluate the predictive utility of the platelet-lymphocyte ratio (PLR) on survival outcomes in NSCLC patients treated with different generations of EGFR TKIs.
- To compare the efficacy of first, second, and third-generation EGFR TKIs in relation to PLR.
Main Methods
- A cohort of 151 patients with NSCLC treated with EGFR TKIs was analyzed.
- Patients were stratified based on the generation of TKI received and pre-treatment PLR levels.
- Progression-free survival (PFS) was assessed using Kaplan-Meier analysis, and changes in laboratory markers were analyzed using Mann-Whitney and Cox Hazard Regression models.
Main Results
- A significantly lower median PFS was observed in patients with a PLR ≥ 180 treated with first or second-generation TKIs (10.5 months) compared to those with PLR < 180 (16.6 months).
- Median PFS was comparable across PLR levels in patients treated with third-generation osimertinib.
- Osimertinib treatment led to significant reductions in absolute lymphocyte count and platelets compared to first or second-generation TKIs.
Conclusions
- The predictive value of PLR is more pronounced with first and second-generation EGFR TKIs than with third-generation TKIs like osimertinib.
- Third-generation TKIs may offer improved efficacy for patients with laboratory markers indicating a poor prognosis.
- Observed changes in peripheral cell counts suggest TKI generation-dependent alterations in the tumor microenvironment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...